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Coronary Plaque
The Missing Link Between Elevated
Biochemical Markers and Adverse
Outcomes in the “Vulnerable” Patient?We greatly appreciate the comments made by Drs. Korosoglou and
Katus regarding our paper (1). The authors acknowledge the
promising potential of plaque quantiﬁcation for individualized
prediction of acute coronary syndrome (ACS). At the same time,
highly-sensitive cardiac troponin T (hsTnT) also has important
prognostic implications, although indeed the pathophysiologic
mechanism is not fully understood. Previous results showed hsTnT
levels to be associated with extent of coronary artery disease (2) and
to have independent prognostic value on top of stenosis severity, as
assessed by cardiac computed tomographic angiography (3). The
suggestion that hsTnT elevation might be a marker of plaque
instability is very interesting and could possibly explain these
ﬁndings. We agree that the association between high-risk plaque
features and hsTnT levels points toward this direction (4). Our
current investigation is really a ﬁrst step to identify the additional
value of coronary plaque quantiﬁcation, and it would be a very
interesting next study to validate serum biomarkers again using
high-risk imaging parameters.
The authors express some methodological concerns. Regarding
selection bias, our objective was to investigate the potential addi-
tional value of plaque quantiﬁcation over conventional cardiac
computed tomographic angiography readings. In fact, we compared
2 methods within the same patient group. That is the reason whywe chose a randomly-selected control population: the inﬂuence of
selection bias would be irrelevant to this comparison. As mentioned
by the authors, the fact that ACS can also occur in the absence of
angiographically-visible coronary artery disease is really an intrinsic
limitation of plaque assessment in general (and could limit its
prognostic value in a prospective study). Unfortunately, predicting
these elusive ACS cases remains challenging. The semiautomated
nature of our quantiﬁcation algorithm results in approximately
15 min operating time per patient and, indeed, some interobserver
variability. For clinical practice, the development of a reliable
automated method would be beneﬁcial.
Most important, a prospective study on plaque quantiﬁcation
could validate our suggested high-risk parameters. This informa-
tion could help us to identify a simple and clinically useful “risk
score” based on imaging data. Combining coronary imaging and
serum biomarkers (such as hsTnT) may possibly further improve
individualized risk assessment. We fully agree with the authors
that, regarding the wide array of novel therapeutic options, this
would be a very important goal to pursue.*Mathijs O. Versteylen, MD
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